Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLE: Tolerization Regimen for Pegloticase in Refractory Gout
NCT02598596Phase 2Completed
- Sponsor
- AMPEL BioSolutions
- Start
- Dec 2015
- Primary completion
- Apr 2020
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegloticase in gout, sponsored by AMPEL BioSolutions. Started Dec 2015; status: completed.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT02598596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598596.